On May 6, 2026 Signadori Bio SAS ("Signadori" or the "Company"), a preclinical-stage biopharmaceutical company developing a next generation, off-the-shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, reported the successful completion of its seed extension financing round, bringing the total raised to €11.1 million. This latest investment was through participation from Taiho Ventures, and existing investors Sofinnova Partners and Invivo Partners.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds from the financing will support the advancement of Signadori Bio’s lead programme SiB-2101 towards lead candidate nomination, further development of its proprietary in vivo monocyte engineering platform, and expansion of its scientific and operational teams.

Signadori Bio is developing a novel immunotherapy approach based on engineering monocytes in vivo to regulate and enhance myeloid anti-tumour activity. By harnessing the innate immune system, the company aims to overcome the immunosuppressive tumour microenvironment and address key limitations of existing immunotherapies and autologous cell therapies, particularly in solid tumours.

"This financing represents an important milestone for Signadori Bio as we continue to build on our promising preclinical data and advance our platform toward the clinic," said Dr. Selwyn Ho, Chief Executive Officer of Signadori Bio. "Our approach to in vivo engineering of monocytes has the potential to unlock a new class of immunotherapies that are more accessible, scalable, and effective for patients with solid tumours. We are delighted to welcome Taiho Ventures alongside our existing investors, Sofinnova Partners and Invivo Partners."

"Signadori Bio is advancing a highly differentiated strategy in immuno-oncology by targeting monocytes and leveraging in vivo engineering," said Seiji Miyahara, Partner & Senior Investment Director at Taiho Ventures, LLC. "The company’s compelling preclinical data and strong scientific foundation position it well to address significant unmet needs in solid tumours. We are excited to support the team in this next phase of development."

"Since inception, Signadori Bio has made strong progress in validating its platform and demonstrating the therapeutic potential of p21-driven monocyte reprogramming," said Matthieu Coutet, Chair of the Board at Signadori Bio and Partner at Sofinnova Partners. "This financing will enable the company to accelerate its development strategy and move closer to clinical translation."

Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, and based on research conducted at Gustave Roussy, Signadori Bio is focused on developing off-the-shelf immunotherapies that reprogram innate immune cells directly in the patient.

(Press release, Signadori Bio, MAY 6, 2026, View Source [SID1234665227])